Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Thermo Fisher (TMO), Eli Lilly & Co (LLY)

Tipranks - Wed Apr 1, 9:04AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Thermo Fisher (TMO) and Eli Lilly & Co (LLY) with bullish sentiments.

End of Quarter Sale - 50% Off TipRanks

Thermo Fisher (TMO)

In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Thermo Fisher. The company’s shares closed last Tuesday at $488.64.

According to TipRanks.com, Ryskin is a 3-star analyst with an average return of 1.1% and a 47.3% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Caris Life Sciences, Inc., and Tempus AI, Inc. Class A. ;'>

Thermo Fisher has an analyst consensus of Strong Buy, with a price target consensus of $668.73, implying a 37.1% upside from current levels. In a report issued on March 24, TipRanks – Google also upgraded the stock to Buy with a $526.00 price target.

See the top stocks recommended by analysts >>

Eli Lilly & Co (LLY)

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Eli Lilly & Co today. The company’s shares closed last Tuesday at $919.00.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 16.0% and a 61.1% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Mineralys Therapeutics, Inc., and Amylyx Pharmaceuticals Inc. ;'>

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $1250.11, implying a 39.9% upside from current levels. In a report issued on March 20, TipRanks – xAI also upgraded the stock to Buy with a $1019.00 price target.

Read More on TMO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.